203 related articles for article (PubMed ID: 33151040)
1. Communication-related assessments in an Angelman syndrome mouse model.
Perrino PA; Chamberlain SJ; Eigsti IM; Fitch RH
Brain Behav; 2021 Jan; 11(1):e01937. PubMed ID: 33151040
[TBL] [Abstract][Full Text] [Related]
2. Excessive Laughter-like Vocalizations, Microcephaly, and Translational Outcomes in the
Berg EL; Jami SA; Petkova SP; Berz A; Fenton TA; Lerch JP; Segal DJ; Gray JA; Ellegood J; Wöhr M; Silverman JL
J Neurosci; 2021 Oct; 41(42):8801-8814. PubMed ID: 34475199
[TBL] [Abstract][Full Text] [Related]
3. Hypersociability in the Angelman syndrome mouse model.
Stoppel DC; Anderson MP
Exp Neurol; 2017 Jul; 293():137-143. PubMed ID: 28411125
[TBL] [Abstract][Full Text] [Related]
4. Seizure-like activity in a juvenile Angelman syndrome mouse model is attenuated by reducing Arc expression.
Mandel-Brehm C; Salogiannis J; Dhamne SC; Rotenberg A; Greenberg ME
Proc Natl Acad Sci U S A; 2015 Apr; 112(16):5129-34. PubMed ID: 25848016
[TBL] [Abstract][Full Text] [Related]
5. Translational outcomes in a full gene deletion of ubiquitin protein ligase E3A rat model of Angelman syndrome.
Berg EL; Pride MC; Petkova SP; Lee RD; Copping NA; Shen Y; Adhikari A; Fenton TA; Pedersen LR; Noakes LS; Nieman BJ; Lerch JP; Harris S; Born HA; Peters MM; Deng P; Cameron DL; Fink KD; Beitnere U; O'Geen H; Anderson AE; Dindot SV; Nash KR; Weeber EJ; Wöhr M; Ellegood J; Segal DJ; Silverman JL
Transl Psychiatry; 2020 Jan; 10(1):39. PubMed ID: 32066685
[TBL] [Abstract][Full Text] [Related]
6. Behavioral Evaluation of Angelman Syndrome Mice at Older Ages.
Dutta R; Crawley JN
Neuroscience; 2020 Oct; 445():163-171. PubMed ID: 31730795
[TBL] [Abstract][Full Text] [Related]
7. Abnormal electrophysiological phenotypes and sleep deficits in a mouse model of Angelman Syndrome.
Copping NA; Silverman JL
Mol Autism; 2021 Feb; 12(1):9. PubMed ID: 33549123
[TBL] [Abstract][Full Text] [Related]
8. Adult
Rotaru DC; van Woerden GM; Wallaard I; Elgersma Y
J Neurosci; 2018 Sep; 38(37):8011-8030. PubMed ID: 30082419
[TBL] [Abstract][Full Text] [Related]
9. Angelman Syndrome: From Mouse Models to Therapy.
Rotaru DC; Mientjes EJ; Elgersma Y
Neuroscience; 2020 Oct; 445():172-189. PubMed ID: 32088294
[TBL] [Abstract][Full Text] [Related]
10. Generation and Characterization of a Novel Angelman Syndrome Mouse Model with a Full Deletion of the
Syding LA; Kubik-Zahorodna A; Nickl P; Novosadova V; Kopkanova J; Kasparek P; Prochazka J; Sedlacek R
Cells; 2022 Sep; 11(18):. PubMed ID: 36139390
[TBL] [Abstract][Full Text] [Related]
11. Rescue of altered HDAC activity recovers behavioural abnormalities in a mouse model of Angelman syndrome.
Jamal I; Kumar V; Vatsa N; Shekhar S; Singh BK; Sharma A; Jana NR
Neurobiol Dis; 2017 Sep; 105():99-108. PubMed ID: 28576709
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a TrkB agonist on spatial and motor learning in the
Schultz MN; Crawley JN
Learn Mem; 2020 Sep; 27(9):346-354. PubMed ID: 32817301
[TBL] [Abstract][Full Text] [Related]
13. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA.
Meng L; Ward AJ; Chun S; Bennett CF; Beaudet AL; Rigo F
Nature; 2015 Feb; 518(7539):409-12. PubMed ID: 25470045
[TBL] [Abstract][Full Text] [Related]
14. Enhanced Nociception in Angelman Syndrome Model Mice.
McCoy ES; Taylor-Blake B; Aita M; Simon JM; Philpot BD; Zylka MJ
J Neurosci; 2017 Oct; 37(42):10230-10239. PubMed ID: 28931574
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Operant Extinction and Prefrontal Excitability in a Mouse Model of Angelman Syndrome.
Sidorov MS; Judson MC; Kim H; Rougie M; Ferrer AI; Nikolova VD; Riddick NV; Moy SS; Philpot BD
J Neurosci; 2018 Mar; 38(11):2671-2682. PubMed ID: 29431654
[TBL] [Abstract][Full Text] [Related]
16. Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant
Lee HM; Clark EP; Kuijer MB; Cushman M; Pommier Y; Philpot BD
Mol Autism; 2018; 9():45. PubMed ID: 30140420
[TBL] [Abstract][Full Text] [Related]
17. Functional rescue in an Angelman syndrome model following treatment with lentivector transduced hematopoietic stem cells.
Adhikari A; Copping NA; Beegle J; Cameron DL; Deng P; O'Geen H; Segal DJ; Fink KD; Silverman JL; Anderson JS
Hum Mol Genet; 2021 Jun; 30(12):1067-1083. PubMed ID: 33856035
[TBL] [Abstract][Full Text] [Related]
18. Decreased Axon Caliber Underlies Loss of Fiber Tract Integrity, Disproportional Reductions in White Matter Volume, and Microcephaly in Angelman Syndrome Model Mice.
Judson MC; Burette AC; Thaxton CL; Pribisko AL; Shen MD; Rumple AM; Del Cid WA; Paniagua B; Styner M; Weinberg RJ; Philpot BD
J Neurosci; 2017 Aug; 37(31):7347-7361. PubMed ID: 28663201
[TBL] [Abstract][Full Text] [Related]
19. Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model.
Silva-Santos S; van Woerden GM; Bruinsma CF; Mientjes E; Jolfaei MA; Distel B; Kushner SA; Elgersma Y
J Clin Invest; 2015 May; 125(5):2069-76. PubMed ID: 25866966
[TBL] [Abstract][Full Text] [Related]
20. Delayed loss of UBE3A reduces the expression of Angelman syndrome-associated phenotypes.
Sonzogni M; Hakonen J; Bernabé Kleijn M; Silva-Santos S; Judson MC; Philpot BD; van Woerden GM; Elgersma Y
Mol Autism; 2019; 10():23. PubMed ID: 31143434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
